



**Important Information about BiDil®  
(isosorbide dinitrate and hydralazine hydrochloride)**

Dear Healthcare Professional:

NitroMed, the maker of BiDil®, which is indicated for the treatment of heart failure in African Americans, continues to be commercially available for you and your patients. However, on January 15, 2008, NitroMed announced that we have made the difficult decision to no longer actively market and promote BiDil. I wish to assure you that we are committed to continue to supply BiDil as a treatment option for prescribers and their African American heart failure patients. Access through retail drug stores and the vast majority of America's healthcare plans will be unchanged. The company's decision to discontinue active promotion will have no impact on insurance coverage or disrupt the ability to prescribe, fill or renew prescriptions, report adverse events and product complaints, obtain BiDil samples, or receive medical and product information.

We pledge to continue to provide the highest quality product to BiDil-treated heart failure patients. NitroMed maintains a high level of compliance with all applicable regulations and laws governing the manufacture, storage and distribution of medicines. We will ensure that the quality and integrity of the BiDil supply remains intact.

BiDil is indicated for the treatment of heart failure as an adjunct to standard therapy in self-identified black patients to improve survival, to prolong time to hospitalization for heart failure, and to improve patient-reported functional status. There is little experience in patients with NYHA class IV heart failure. Most patients in the clinical trial supporting effectiveness (A-HeFT) received a loop diuretic, an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker, and a beta blocker, and many also received a cardiac glycoside or an aldosterone antagonist. Full prescribing information is available at <http://www.bidil.com/>.

NitroMed intends to keep certain key resources and programs in place:

- To report an adverse event or product complaint, or request medical or product information please call 1-888-692-4345. Alternatively, you can dial the main NitroMed telephone number and follow the instructions, 1-888-992-4338.
- Eligible healthcare professionals can request samples of BiDil at <http://www.bidil.com/>.


- Information about BiDil<sup>®</sup> will remain available for healthcare providers and patients at <http://www.bidil.com/>.
- The patient assistance program, NitroMed Cares<sup>™</sup> is ongoing. Dial NitroMedCares at 1-800-956-0695 or visit our website at <http://www.bidil.com/>.
- On-line continuing medical education programs will remain active on <http://www.theheart.org/index.do> through October, 2008.

For your insured patients, bear in mind that BiDil<sup>®</sup> is broadly available on most commercial and Medicare drug plans at affordable co-payments.

NitroMed is continuing development efforts to commercialize an extended release, once-daily dosing formulation of BiDil<sup>®</sup>, BiDil-XR. In addition, the company is evaluating strategic opportunities that may allow for the resumption of marketing and promotional activities.

If you have any questions or would like additional information, please contact the appropriate number listed above or contact me directly at 781-266-4218 or [woneal@nitromed.com](mailto:woneal@nitromed.com).

Sincerely,



Welton O'Neal, Pharm.D.  
Vice President, Medical Affairs